| Sep 16 |
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
|
| Sep 4 |
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 14 |
Apollomics GAAP EPS of -$0.38
|
| Aug 14 |
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
|
| Aug 13 |
Apollomics stock rallies 30% on Phase 2 vebreltinib data
|
| Aug 13 |
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
|
| Aug 8 |
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
|
| Jul 18 |
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
|
| Jul 16 |
Apollomics receives 180-day extension to regain compliance with Nasdaq
|
| Jul 16 |
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
|
